Study finds 89% of patients treated for persistent atrial fibrillation using abbott's ablation device remain symptom-free for at least 15 months

Treatment with the tacticath™ contact force ablation catheter, sensor enabled™ resulted in patients with persistent atrial fibrillation experiencing an improved quality of life the catheter is part of abbott's suite of electrophysiology solutions designed to improve procedures to address cardiac arrythmias abbott park, ill., april 29, 2022 /prnewswire/ -- abbott (nyse: abt) today announced results from the persist-end study, which showed that nearly nine out of 10 patients (89%) treated for persistent atrial fibrillation (afib) with the company's tacticath™ contact force ablation catheter, sensor enabled™ (tacticath se) remained symptom-free for up to 15 months following the procedure.
ABT Ratings Summary
ABT Quant Ranking